About AM-pharma

AM-Pharma’s purpose is to save and improve the lives of patients confronted with severe medical conditions. Our focus is acute on chronic kidney injury, impacting hundreds of thousands of people hospitalized each year. Our proprietary compound, ilofotase alfa, has the potential to become the first treatment for acute kidney injury and its safety and a potential reno-protective effect has been demonstrated in global clinical trials involving approximately 1,000 subjects. In addition, based upon preclinical data showing improved overall survival and restored phenotypes associated with hypophosphatasia (HPP) as well as a biomarker dose response in adult patients with HPP treated with ilofotase alfa, we are developing ilofotase alfa as a potential enzyme replacement therapy in HPP. We are a dedicated team driven to bring treatment options to severely ill patients, their families and health care professionals.


AM-Pharma strives AM-Pharma strives to develop medicines for patients confronted with severe medical conditions. Our proprietary asset, ilofotase alfa, is being developed for the treatment of patients with acute on chronic kidney injury and has been granted FDA fast-track status and for patients with hypophosphatasia, an orphan disease for which we have orphan drug designation granted by the FDA and EMA.

Our investors